Get the Stockscreener App
19.75
0.20%
0.04
After Hours:
19.53
-0.22
-1.11%
Immunome Inc stock is traded at $19.75, with a volume of 1.96M.
It is up +0.20% in the last 24 hours and down -0.05% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
See More
Previous Close:
$19.71
Open:
$19.65
24h Volume:
1.96M
Relative Volume:
1.05
Market Cap:
$2.18B
Revenue:
$12.59M
Net Income/Loss:
$-212.39M
P/E Ratio:
-6.4013
EPS:
-3.0853
Net Cash Flow:
$-185.92M
1W Performance:
-6.75%
1M Performance:
-0.05%
6M Performance:
+123.42%
1Y Performance:
+76.34%
1-Day Range:
$19.15
$19.84
1-Week Range:
$19.15
$21.66
52-Week Range:
$5.1501
$25.30
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
19.75 | 2.17B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-01-25 | Initiated | Truist | Buy |
| Sep-22-25 | Initiated | Goldman | Buy |
| Sep-05-25 | Initiated | Craig Hallum | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Is Immunome Inc. stock supported by strong fundamentals2026 world cup usa national team semifinals playmakers pressing system odds analysis analysis - Улправда
Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update - ts2.tech
Immunome’s Stock Under the Microscope: Can IMNM Turn Recent Volatility Into a Breakout? - AD HOC NEWS
Immunome (NASDAQ:IMNM) Shares Down 7%Time to Sell? - MarketBeat
Decliners Report: Can Immunome Inc stock deliver strong Q4 earningsJuly 2025 Outlook & Weekly High Return Opportunities - moha.gov.vn
Understanding the Setup: (IMNM) and Scalable Risk - Stock Traders Daily
Top Executive Makes Bold Move With Fresh Immunome Stock Purchase - TipRanks
Insider Buying: Clay Siegall Acquires Additional Shares of Immun - GuruFocus
Immunome (NASDAQ:IMNM) CEO Purchases $100,018.35 in Stock - MarketBeat
Immunome (IMNM) CEO Siegall buys $100k in shares By Investing.com - Investing.com Nigeria
Immunome (IMNM) CEO Siegall buys $100k in shares - Investing.com India
Top Biotech Stocks To ConsiderDecember 15th - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Immunome (IMNM) - The Globe and Mail
Why Immunome stock surged today - MSN
Immunome (IMNM): Assessing Valuation After Strong Phase 3 Varegacestat Data and $400 Million Equity Raise - Sahm
Immunome (IMNM) price target increased by 33.44% to 34.94 - MSN
Immunome, a top 3% stock, just delivered a 'knockout' to Merck KGaA - MSN
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 383,200 Shares - MarketBeat
Guggenheim reiterates Buy rating on Immunome stock following $400M financing By Investing.com - Investing.com South Africa
Guggenheim reiterates Buy rating on Immunome stock following $400M financing - Investing.com Nigeria
Hedge Fund and Insider Trading News: Michael Hintze, Xavier Majic, Stanley Druckenmiller, Warren Buffett, Bill Ackman, Bridgewater Associates, Citadel Investment Group, Infini Capital, Immunome Inc (IMNM), White Mountains Insurance Group Ltd (WTM), a - Insider Monkey
Siegall buys Immunome (IMNM) shares worth $149k By Investing.com - Investing.com Nigeria
Immunome (NASDAQ:IMNM) Insider Purchases $204,900.00 in Stock - MarketBeat
Siegall buys Immunome (IMNM) shares worth $149k - Investing.com India
Tsai Philip buys $204,899 in Immunome stock By Investing.com - Investing.com South Africa
Tsai Philip buys $204,899 in Immunome stock - Investing.com
Immunome CTO Philip Tsai Buys 10,000 Shares - TradingView — Track All Markets
Will Immunome Inc. stock see insider buyingMarket Growth Summary & Verified Swing Trading Watchlist - Улправда
Clay Siegall Bought 5.8% More Shares In Immunome - simplywall.st
Immunome Chairman Acquires 5.8% More Stock - Yahoo Finance
Aug Breakouts: Will Immunome Inc. stock see insider buyingWeekly Profit Report & Free AI Powered Buy and Sell Recommendations - Улправда
How institutional buying supports Immunome Inc. stock2025 Biggest Moves & Fast Moving Stock Trade Plans - ulpravda.ru
Immunome Inc. Stock (IMNM) Opinions on Phase 3 RINGSIDE Trial Results - Quiver Quantitative
Can Immunome Inc. stock deliver strong Q4 earnings2025 Macro Impact & Low Volatility Stock Recommendations - DonanımHaber
Immunome’s Varegacestat shows dramatic results in Phase 3 desmoid tumor trial - Indian Pharma Post
Portfolio Recap: How institutional buying supports Immunome Inc. stockProduct Launch & AI Powered Buy/Sell Recommendations - ulpravda.ru
Aug Breakouts: Why Immunome Inc. stock remains resilient2025 Geopolitical Influence & AI Driven Price Forecasts - Улправда
Insider Buying: Clay Siegall Acquires 46,511 Shares of Immunome Inc (IMNM) - GuruFocus
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunome Inc Stock (IMNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barchas Isaac | Director |
Dec 22 '25 |
Sale |
21.74 |
383,200 |
8,330,080 |
2,031,181 |
| SIEGALL CLAY B | President and CEO |
Dec 19 '25 |
Buy |
20.48 |
7,278 |
149,053 |
860,525 |
| Tsai Philip | Chief Technical Officer |
Dec 19 '25 |
Buy |
20.49 |
10,000 |
204,900 |
43,300 |
| SIEGALL CLAY B | President and CEO |
Dec 18 '25 |
Buy |
21.50 |
46,511 |
999,986 |
853,247 |
| Higgins Jack | Chief Scientific Officer |
Sep 10 '25 |
Option Exercise |
1.35 |
22,000 |
29,700 |
40,729 |
| BIENAIME JEAN JACQUES | Director |
Jun 03 '25 |
Buy |
9.38 |
5,000 |
46,900 |
36,415 |
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):